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ABSTRACT 
Acute kidney injury is a common complication in the intensive care unit. Mortality in critically ill patients 
requiring dialysis is unacceptably high, despite significant advances in the care of the critically ill with AKI. 
The discussion whether continuous or intermittent renal replacement therapy is the preferred modality of 
choice in these patients has decades and the two main factors for decision are: the availability and experi-
ence with a specific treatment, and the haemodynamic status of the patient. Multiple studies have tried to 
establish the best treatment option in terms of patient and renal survival for critically ill patients requiring 
dialysis. In this revision I will try to summarize the available evidence on this topic.
Key-words: Acute kidney injury; continuous renal replacement therapy; intensive care unit; intermittent 
dialysis.
RESUMO 
A lesão renal aguda é uma complicação comum nas unidades de cuidados intensivos. A mortalidade 
do doente crítico que requer diálise é extremamente elevada, apesar dos avanços significativos dos 
cuidados prestados a estes doentes. Há várias décadas que se discute o tipo de modalidade dialítica a 
oferecer a estes doentes (continua ou intermitente) e os principais fatores que pesam na decisão clínica 
são os meios e a experiência do centro, bem como a condição clínica do doente. Vários estudos tentaram 
estabelecer a melhor abordagem ao doente crítico com lesão renal aguda e necessidade dialítica, em 
termos de sobrevida do doente e recuperação renal. Nesta revisão tentarei resumir as evidências disponíveis 
sobre este tema.
Palavras-chave: Lesão renal aguda; diálise intermitente; técnicas contínuas; unidade de cuidados intensivos.
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INTRODUCTION 
Acute kidney injury (AKI), characterized by sudden 
impairment of kidney function, is a common com-
plication in critically ill patients, occurring in 30% to 
60%1 -3 and leading to decreased survival. The Acute 
Dialysis Quality Initiative Workgroup, in 2004, devel-
oped a set of criteria for defining and classifying 
AKI, i.e., the RIFLE classification, in which AKI is 
classified according to its severity4. In September 
2005, a new classification was proposed by the Acute 
Kidney Injury Network (AKIN), the AKIN classification, 
introducing small though important modifications to 
RIFLE5. Lopes JA6 published a good review of the 
definition of AKI in the latest issue of this Journal.
Acute kidney injury severe enough to require renal 
replacement therapy (RRT) involves roughly 5% of 
intensive care unit (ICU) patients1,2 and is associated 
with increased mortality that can reach 60% to 80%7,8. 
So, mortality rates remain unacceptably high despite 
significant advances in the care of the critically ill with 
AKI9. The decision of beginning dialysis in a critically 
ill patient can lead to disagreement among clinicians, 
since the therapeutic aims, the optimal timing for initia-
tion, the dosing and the modality remain uncertain.
Conventional indications for RRT include hyperkalae-
mia or severe metabolic acidosis and fluid overload, not 
controlled by medical treatment, or uremic symptoms 
and treatment of poisoning with a few agents10, in order 
to preserve the life of the patient, allowing for organ 
recovery. Worth mentioning that fluid overload has 
recently been claimed as a major outcome determinant 
of critically ill patients with AKI, and it seems that, besides 
associated with mortality, fluid overload may also be 
associated with a decreased likelihood of renal recovery11. 
This suggests the need to decrease fluid administration 
in patients with AKI or to target negative fluid balance 
during RRT in these patients12. Dialysis is also used in 
some non -renal indications based on the presumed 
elimination of inflammatory mediators, on the removal 
of fluid or elimination of other endogenous toxic sol-
utes13, for instance in sepsis, acute respiratory distress 
syndrome and congestive heart failure. These indications 
are limited and not established, as currently we have 
insufficient data to recommend that14, 15. In fact, a very 
recent randomized trial involving patients hospitalized 
for acute congestive heart failure, worsened renal func-
tion and persistent congestion, showed that a stepped 
pharmacologic therapy algorithm is superior to a strategy 
of ultrafiltration for the preservation of renal function, 
with fewer adverse events16.
Timing of initiation of RRT in critically ill patients 
with AKI is an unresolved issue, and some studies 
and a recent meta -analysis evidence for early institu-
tion of RRT, since this approach may lead to benefit 
on survival17, 18. Nevertheless, overall design and 
quality of studies comparing the two strategies 
(“early” versus “late”) is low18. Further research on 
this is necessary.
The delivery of dialysis dose is another controver-
sial problem, and two randomized controlled studies 
(RENAL and ATN), compared an intensive treatment 
strategy with a more conventional renal support19, 
20 (Table I). Both showed that more intensive RRT 
dose did not improve patient survival, recovery of 
kidney function, or duration of RRT and, therefore, 
the conventional dosing is the recommended (effluent 
flow rate target of 20 -25 ml/Kg/h).
In this article I will describe briefly the different 
RRT modalities used in critically ill patients, and 
review the relevant randomized trials that compare 
these modalities with the aim of summarizing the 
available evidence on this topic.
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Table I
Brief design of the ATN and RENAL studies
ATN RENAL
Intensive Treatment Conventional Treatment Intensive Treatment Conventional Treatment
Hemodynamically stable
IHD 6x week 3x week
Haemodynamically unstable
CVVHDF 35 ml/Kg/h 20 ml/Kg/h 40 ml/Kg/h 25 ml/Kg/h
SLED 6x week 3x week
IHD – intermittent haemodialysis; CVVHDF – continuous veno -venous haemodiafiltration; SLED – slow low efficiency dialysis
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Renal replacement therapy in critically ill patients – what modality should we choose?
RRT IN CRITICALLY ILL PATIENTS 
When we decide to dialyse a critically ill patient 
in an ICU, the first thing to do is to choose the 
modality to use:
– intermittent haemodialysis (IHD) – conventional, 
3 times a week / 4h; or hybrid, also known as 
slow low -efficient dialysis (SLED);
– continuous renal replacement therapy (CRRT) 
– continuous venovenous (CVV) RRT; peritoneal 
dialysis (PD); or slow continuous ultrafiltration 
(SCUF).
The discussion whether CRRT or IHD is the preferred 
modality of choice for RRT in the ICU has decades, 
and it appears that most nephrologists preferred IHD, 
whereas intensivists preferred CRRT7, since the intro-
duction of this modality in the clinical practice in the 
late 1970s/early 1980s was to compensate the inad-
equacies of the IHD in the treatment of critically ill 
patients with multiple -organ failure21.
Peritoneal dialysis, as a CRRT, could also be used, 
but there is lack of evidence in AKI adults patients, 
in view of the fact that the studies are generally 
confine to paediatrics, reports in adults are mainly 
uncontrolled observations, and, contrary to what 
occurs in developing countries, it is infrequently used 
in AKI in high -income countries. Currently, indications 
may include bleeding diathesis, haemodynamic insta-
bility and difficulty in obtaining vascular access22. 
Nevertheless, complications with this technique in 
an ICU are high and include protein loss, peritonitis, 
ventilator compromise or high glucose levels.
Slow continuous ultrafiltration is used mainly as 
a dehydrating procedure for fluid removal by filtra-
tion and, when solute control is important, it has to 
be supplemented with either IHD or CRRT.
When selecting the modality, the two main factors 
are: the availability and experience with a specific 
treatment, and the patient´s haemodynamic status. 
If the patient is haemodynamic stable, we have no 
doubt, and the patient does conventional IHD. If the 
patient is unstable, and both modalities are available, 
we can choose IHD/SLED or CRRT22. Both can provide 
solute removal by diffusive small -solute transport 
(haemodialysis), convective small - and medium -solute 
transport (haemofiltration – HF) or by the combination 
of diffusive and convective solute transport (haemo-
diafiltration – HDF), using low – or high -flux dialyzers 
for haemodialysis and high -flux dialyzers for haemo-
filtration and haemodiafiltration.
SLED 
Slow low -efficient dialysis is a hybrid haemodialysis 
that has emerged as a viable alternative to conventional 
IHD and to CRRT in the treatment of AKI patients, and 
employs characteristics of both modalities23, combining 
advantages of CRRT with the practicality of IHD. First 
described in 198823, SLED uses the conventional IHD 
equipment, but with a slower clearance of solutes and 
volume [blood flow (Qb) of 100 -300 ml/min and dialysate 
rates (Qd) of 200 -500 ml/min; Ultrafiltration 150 ml/h], 
for extended periods of time (6 -12h/day). Comparing to 
conventional IHD, it offers less small solutes disequilib-
rium, provides effective control of azotaemia and confers 
better haemodynamic tolerance to ultrafiltration.
Its popularity is gained because it is easy, safe, con-
venient, effective and less expensive than CRRT, with 
similar outcomes to other modalities23. It is likely that 
this modality offers an additional advantage for con-
ventional IHD, but this remain to be proven (Table II).
CRRT 
The patient with severe haemodynamic instability 
often cannot tolerate conventional intermittent 
Table II
Comparison between SLED and CRRT
SLED CRRT
Lower cost Higher cost
Easy to perform Hard to perform, requiring trained 
nurses
Conventional equipment Complex equipment
Anticoagulation with Heparin Anticoagulation with Heparin or 
Citrate
Higher fluid shifts Haemodynamic stability
Reduced risk for cerebral oedema
Less exposure to anticoagulation Higher risk for bleeding and hypo-
thermia
SLED – slow low efficiency dialysis; CRRT – continuous renal replacement therapy
Nefro - 27-2 - MIOLO.indd   85 26-06-2013   15:08:08
86    Port J Nephrol Hypert 2013; 27(2): 83-89
CMYKP
treatments or even SLED. Continuous renal replacement 
therapy is generally well tolerated, because it has slower 
fluid removal, resulting in more haemodynamic stability, 
fewer episodes of renal ischaemia, better control of 
fluid balance, avoidance of fluid shifts, and reduced 
risk of cerebral oedema (Qb 100 -200ml/min; dialysate 
rates of 1000 -2000 ml/min; effluent volume 20 -30 ml/
Kg/h)21, 22. Continuous therapies perform slow correction 
of AKI leading to a steady -state condition very similar 
to that provided by native kidneys21, but frequently 
delivered dose is different (and lower 10% to 15%) from 
prescribed dose, most likely due to treatment down-
time19,20. Nevertheless, there are some disadvantages: 
CRRT uses different and complex equipment, requiring 
trained nurses for carrying out the technique, leading 
to higher costs. Besides, it requires immobilization of 
the patient, there is a risk of hypothermia, and the need 
for prolonged anticoagulation may increase bleeding 
risk. Regional heparin/protamine and citrate are safe, 
but underused. Citrate should be used with caution in 
patients in shock and in patients with severe liver failure. 
Its use requires an established protocol with instructions 
for infusion of citrate and calcium, composition of the 
dialysate/replacement fluid, and intensive metabolic 
monitoring, including acid -base status, sodium and total/
ionized calcium levels22 (Table II).
 RRT IN ICU PATIENTS – WHAT DO  
STUDIES TELL US
Multiple observational and retrospective studies 
have tried to establish the best treatment option for 
critically ill patients requiring dialysis. In the 1990s, 
retrospective non -randomized studies reported that 
patients who received CRRT (using synthetic mem-
branes) had a better survival rate than patients who 
received IHD (with cuprophan membranes)24 -26; on 
the other hand, observational or randomized studies 
with selection bias showed that patients who received 
IHD had a lower mortality rate, doubtless because 
CRRT was chosen for the worse cases27,28.
Since 2000 until the present, several randomized 
controlled studies have been published with the 
same thematic: to try to find the best patient care 
and renal survival benefits when using one technique 
or another.
I chose four such studies (Table III) attempting to 
answer the question: what is the best modality to 
dialyze a critically ill patient with AKI?
The first study was published, in 2004, by Augus-
tine and co -workers29. They reviewed all cases of 
patients with AKI requiring dialyses that had been 
admitted to the ICU of the Cleveland Clinic, between 
November 1995 and January 1999. Exclusion criteria 
were previous dialysis treatment/kidney transplant, 
permanence in ICU less than 48h, or inability to 
obtain informed consent.
Of the 105 patients admitted to ICU with inclusion 
criteria, 80 were randomized, according to the Cleve-
land Clinic Foundation severity score: 40 patients to 
CRRT (CVVHD; Qb 200 ml/min) and 40 patients to IHD 
(Qb 300 ml/min, Qd 500 ml/min, 3 times a week, and 
variable treatment time). Overall hospital mortality was 
Table III
Randomized trials comparing CRRT and IHD in AKI patients in ICU.
Study n Design Mortality Comments
Augustine et al. (2004)   80 Single -centre RCT
CVVHD (40) vs IHD (40)
68% vs 70%
(p = ns)
CRRT patients achieve greater volume removal
Vinsonneau et al. (2006) 359 Multicentre RCT
CVVHDF (175) vs IHD (184)
33% vs 32%
at day 60
(p = ns)
Hypothermia as an adverse event on CVVHDF
Lins et al. (2009) 316 Multicentre RCT
CVVHF (172) vs IHD (144)
58.1% vs 62.5%
(p = ns)
Some haemodynamic instable patients excluded
Van Berendoncks (2010) 595 Multicentre RCT
Long -term survivors (413) vs non -survivors 
(182) 2 years after discharge
30.6% died
2 years after discharge
Modality of RRT had no influence in long -term 
survival (2 years) after AKI
CRRT – continuous renal replacement therapy; IHD – intermittent haemodialysis; AKI – acute kidney injury; ICU – intensive care unit; RCT – randomized controlled trial; CVVHD – 
continuous veno -venous haemodialysis; IHD – intermittent haemodialysis; CVVHDF – continuous veno -venous haemodiafiltration; CVVHF – continuous veno -venous haemofiltration.
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high and similar in both groups (CRRT 67.5%; IHD 
70%, p > 0.05); urine output significantly declined in 
both groups, without differences between modalities. 
Total fluid balances were markedly different between 
groups during the first 3 days on dialysis, the median 
cumulative total fluid balance was negative ( - 4005 
ml) for the CRRT group, and was positive (+1539 ml) 
for the IHD group (p < 0.001). This difference was 
probably related with haemodynamic instability in the 
former group. Moreover 40% of IHD patients required 
more vasopressors during dialysis (p = 0.005). Also 
changes and the mean decline in MAP on dialysis were 
different between the two groups: there was a signifi-
cant decrease in MAP for the IHD patients from the 
baseline within 72h of dialysis therapy, otherwise MAP 
remained unchanged on CRRT therapy; the mean 
decline was high also in IHD patients (p = 0.047 for 
the difference between groups). The authors concluded 
that mortality in critically ill patients requiring dialysis 
treatment is high, but the modality choice had no 
impact on renal or patient survival. Even though, CRRT 
patients achieved greater volume removal preserving 
haemodynamic stability.
The second, the HEMODIAFE Study30, was performed 
in 21 French intensive care units, from October 1999 
to March 2003, with AKI and RRT patients with multiple-
-organ dysfunction syndrome (MODS). Exclusion criteria 
were obstructive/vascular AKI, pregnancy, age (< 18 
years), chronic kidney disease (CKD), use of ACEi after 
admission, haemorrhagic diathesis, SAPS II< 37, mori-
bund state/survival expectancy of less than 8 days. The 
authors randomized 359 patients: 184 for IHD (Qb ≥ 
250 ml/min; Qd 500 ml/min; sodium 150 mmol/L; dia-
lysate temperature 35 °C, treatment time at least 4h); 
175 for CRRT (CVVHDF predilutional; Qb ≥120 ml/min; 
Qd ≥ 500 ml/h; ultrafiltration flow of 1000ml/h). Switches 
between treatments were authorized and six patients 
were switched from IHD to CRRT (haemodynamic insta-
bility, technical problems, unauthorized switch) and 31 
from CRRT to IHD [14 for a planned reason (resolved 
MODS) and 17 due to technical problems, bleeding or 
risk of bleeding and lack of efficiency].
There was no difference in 60 -day survival (32% 
IHD; 33% CRRT), length of stay in hospital/ICU, or 
recovery of renal function. Adverse events were 
similar between the two modalities, except for hypo-
thermia that occurred less often in IHD modality. 
Of note, mean volume loss during each treatment 
did not differ between the groups, and there were 
no differences in the incidence of severe arterial 
hypotension between the two groups. The authors 
concluded that virtually all patients could be treated 
with IHD provided that measures were implemented 
to prevent haemodynamic instability.
The third study was published in Nephrology 
Dialysis Transplantation, in 2009, by the ivestiga-
tors of the Stuivenberg Hospital Acute Renal Failure 
(SHARF) project31, a predictive model for hospital 
mortality in patients admitted to ICU. The SHARF 
score was developed in SHARF 1 and SHARF 2 
studies32, and validated in SHARF 3 study33. The 
present study is the SHARF 4, which was designed 
to compare hospital and renal survival in patients 
with AKI requiring dialysis. All adult AKI patients 
with a serum creatinine ≥ 2 mg/dl, admitted to 9 
Belgian ICU, between April 2001 and March 2004, 
were registered; randomization occurred when RRT 
was necessary, and patients were stratified in three 
classes of disease severity, according to the SHARF 
score (< 30; 30 -60; > 60) and within each stratum, 
patients were randomized to daily IHD (Qb 100 -300 
ml/min; Qd 300 -500 ml/min, 4 -6h), or CRRT (post-
-dilution CVVHF; Qb 100 -250 ml/min; ultrafiltration 
rate of 1 -2L/h). Exclusion criteria were age (< 18 
years) and CKD. Of the 1303 patients enrolled, 650 
required RRT and 316 were randomized: 144 patients 
for IHD and 172 for CRRT. Of note, 344 patients 
were excluded by either non -medical reasons (54%) 
or medical reasons (in 37% – coagulations distur-
bances or haemodynamic instability perhaps 
because the authors believed it was incompatible 
with the use of IHD). Overall mortality was 60.1% 
(62.5% for IHD; 58.1% for CRRT, p=0.430) and no 
difference in mortality between both treatment 
options could be observed within each of the three 
SHARF classes. The authors concluded that, in this 
controlled randomized trial with stratification 
according to disease severity, mortality rates, the 
length of hospital and ICU stay, and renal function 
at hospital discharge were comparable for both 
treatment options.
The last study I chose was published in 201034. 
In continuity with the previous study using the same 
database, the authors searched the patients with 
AKI who survived to hospitalization, at 2 years after 
discharge. The survivors of the SHARF 4 were used 
for the follow -up to investigate long -term mortality, 
renal function, co -morbidity and quality of life.
Renal replacement therapy in critically ill patients – what modality should we choose?
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Of the 1303 patients enrolled, only 595 survived 
hospitalization after AKI. The first conclusion was that 
AKI is a very severe disease. Of the 595, 182 died 
within 2 years after discharge (non -survivors), and 
413 (survivors) were eligible for further investigation. 
Comparing survivors at 2 years with non -survivors, 
the latter were older (p < 0.001), proportionally more 
male (p = 0.036), and mean creatinine clearance at 
discharge was significantly lower (p = 0.030). Binary 
logistic regression analysis noticed only age and gen-
der as independent predictors of long -term mortality. 
No differences between survivors and non -survivors 
were observed in disease severity, length of ICU or 
hospital stay, late ICU admission, type or cause of 
AKI, neither treatment modality (conservative treat-
ment, IHD, CRRT). The authors confirmed the poor 
prognosis of AKI, with a hospital mortality rate of 
50.7%, and showed that sepsis, ventilation, late ICU 
admission were not predictive for long -term mortality, 
as they are in predicting mortality in ICU and hospital. 
The authors also confirmed that the modality of RRT 
has no influence in long -term outcome of AKI. Of the 
survivors, only 204 received a home visit (142 were 
lost to follow -up and 67 did not consent): a consider-
able part of survivors stayed in need of chronic RRT 
(21 patients) and survivors had important co -morbid-
ities (peripheral vascular disease, peptic ulcer disease, 
diabetes and myocardial infarction).
THE MESSAGE LEARNED 
These studies suggest that dialysis modality does 
not influence mortality. Despite the theoretical benefit 
of CRRT, no study has clearly proved it. But we must 
bear in mind that none of the studies was perfect: 
the studies were small (only two included more than 
300 patients and were prospective, randomized, and 
multicentred in design30,31), the exclusion of the 
“very” haemodynamic unstable31; absence of a com-
parison of the delivered dose of dialysis with both 
modalities29 -32; absence of comparison between 
SLED and CRRT or even conventional IHD and SLED; 
comparison between continuous haemodiafiltration 
versus standard intermittent haemodialysis30 -32, were 
some of the biases encountered.
Given the lack of evidence, some researchers have 
suggested that CRRT is not cost -effective when com-
paring to IHD35.
However there are some exceptions where CRRT 
must be used22,36:
1. In critically ill AKI patients with severe haemo-
dynamic instability, as Augustine and co -work-
ers showed29. SLED may also be tolerated in 
situations where CRRT is not available22.
2. In patients with acute brain injury or increased 
intracranial pressure or generalized brain oede-
ma, as occurs in trauma or hepatorenal syn-
drome. IHD is associated with fluid shifts and 
can exacerbate dialysis disequilibrium, resulting 
in increase of cerebral oedema and intracranial 
pressure. This situation can be avoided with 
CRRT22,36 -39.
So, in conclusion, no RRT is ideal for all patients 
with AKI. Also, CRRT and IHD should be seen as 
complementary therapies in AKI patients22,36. Both 
modalities are possible in the majority of AKI criti-
cally ill patients, considering, however, that there 
are particular situations that benefit more with CRRT. 
Clinicians should look for the patient instead of the 
disease, when choosing RRT.
Conflict of interest statement. None declared.
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